Neratinib as extended adjuvant therapy in patients with HER2-positive/HR-positive early breast cancer: German HTA-driven analyses from the ExteNET study

Neratinib as extended adjuvant therapy in patients with HER2-positive/HR-positive early breast cancer: German HTA-driven analyses from the ExteNET study

Bibliographic Details
Main Authors: D. Lüftner, H. Tesch, M. Schmidt, A. Hartkopf, S. Streicher, A. Resch, L. Genovese, C. Rosé, R. Valenti, N. Harbeck
Format: Article
Language:English
Published: Elsevier 2021-04-01
Series:Breast
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977621000898

Internet

http://www.sciencedirect.com/science/article/pii/S0960977621000898

Similar Items